TY - JOUR
T1 - Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity
AU - Sharaiha, Reem Z.
AU - Hajifathalian, Kaveh
AU - Kumar, Rekha
AU - Saunders, Katherine
AU - Mehta, Amit
AU - Ang, Bryan
AU - Skaf, Daniel
AU - Shah, Shawn
AU - Herr, Andrea
AU - Igel, Leon
AU - Dawod, Qais
AU - Dawod, Enad
AU - Sampath, Kartik
AU - Carr-Locke, David
AU - Brown, Robert
AU - Cohen, David
AU - Dannenberg, Andrew J.
AU - Mahadev, Srihari
AU - Shukla, Alpana
AU - Aronne, Louis J.
N1 - Funding Information:
Reem Z. Sharaiha, MD, MSc (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Writing ? original draft: Lead; Writing ? review & editing: Lead), Kaveh Hajifathalian, MD (Formal analysis: Equal; Writing ? original draft: Equal), Rekha Kumar, MD (Writing ? review & editing: Supporting), Katherine Saunders, MD (Writing ? review & editing: Supporting), Amit Mehta, MD (Data curation: Equal; Writing ? review & editing: Supporting), Bryan Ang, MD (Data curation: Supporting), Daniel Skaf, MD (Data curation: Supporting), Shawn Shah, MD (Data curation: Supporting; Writing ? review & editing: Supporting), Andrea Marie Herr, RN (Data curation: Supporting), Leon Igel, MD (Writing ? review & editing: Supporting), Qais Maher Dawod, MD (Data curation: Equal), Enad Dawod, MD (Data curation: Supporting), Kartik Sampath, MD (Writing ? review & editing: Supporting), David Carr-Locke, MD (Writing ? review & editing: Supporting), Robert Brown, MD (Writing ? review & editing: Supporting), David Cohen, MD (Writing ? review & editing: Supporting), Andrew J. Dannenberg, MD (Writing ? review & editing: Supporting), Srihari Mahadev, MD (Writing ? review & editing: Supporting), Alpana Shukla, MD (Writing ? review & editing: Supporting), Louis J. Aronne, MD (Writing ? review & editing: Equal) Conflicts of interest These authors disclose the following: Reem Z. Sharaiha is a Consultant for Boston Scientific, Cook Medical, Lumendi, and Olympus. Katherine Saunders is a Consultant and has equity interests in Intellihealth/BMIQ. Rekha Kumar reports receiving consulting fees from Intellihealth; serving as a speaker for Novo Nordisk and Janssen Pharmaceuticals; and having equity interests in Vivus, Zafgen, and Myos Corporation. Louis J. Aronne reports receiving consulting fees from and serving on advisory boards for Jamieson Laboratories, Pfizer, Novo Nordisk, Eisai, Real Appeal, Janssen, and Gelesis; receiving research funding from Aspire Bariatrics, Allurion, Eisai, AstraZeneca, Gelesis, Janssen, and Novo Nordisk; having equity interests in Intellihealth/BMIQ, ERX, Zafgen, Gelesis, MYOS, and Jamieson Laboratories; and serving on a board of directors for Intellihealth/BMIQ, MYOS, and Jamieson Laboratories. The other authors disclose no conflicts.
Publisher Copyright:
© 2021 AGA Institute
PY - 2021/5
Y1 - 2021/5
N2 - Background And Aims: The growing burden of obesity as a chronic disease necessitates a multifaceted approach to management. There has been an increase in the number of available endoscopic therapies for weight management with endoscopic sleeve gastroplasty (ESG) proving to be one of the best options. The long-term efficacy of ESG for management of obesity is not known. This study sought to assess the long-term safety and efficacy of ESG for treatment of obesity. Methods: This was a prospective cohort study. Participants underwent ESG in a single academic center, and were prospectively enrolled. All procedures were performed by the same therapeutic endoscopist. Patients with a body mass index of >30 kg/m2 (or >27 with comorbidities), who underwent ESG from August 2013 to August 2019 for treatment of obesity were enrolled. Patients were followed for up to 5 years after their procedure. The primary outcome was weight loss at 5 years after the procedure (% total body weight loss, TBWL) Results: 216 patients (68% female) with a mean age of 46±13 years, and mean BMI of 39±6 kg/m2 underwent ESG. Out of 216 patients, 203, 96, and 68 patients were eligible for a 1-, 3-, and 5-year follow up, with complete follow-up rates of 70%, 71%, and 82%, respectively. At 5 years, mean TBWL was 15.9% (95% CI, 11.7-20.5, p < .001) and 90 and 61% of patients maintained 5 and 10% TBWL, respectively. There was an overall rate of 1.3% moderate adverse events (AEs), without any severe or fatal AEs. Conclusions: Our results suggest that ESG is safe and effective for treatment of obesity, with durable long-term results for at least up to 5 years after the procedure. This procedure should be considered as a reliable option for treatment of obesity.
AB - Background And Aims: The growing burden of obesity as a chronic disease necessitates a multifaceted approach to management. There has been an increase in the number of available endoscopic therapies for weight management with endoscopic sleeve gastroplasty (ESG) proving to be one of the best options. The long-term efficacy of ESG for management of obesity is not known. This study sought to assess the long-term safety and efficacy of ESG for treatment of obesity. Methods: This was a prospective cohort study. Participants underwent ESG in a single academic center, and were prospectively enrolled. All procedures were performed by the same therapeutic endoscopist. Patients with a body mass index of >30 kg/m2 (or >27 with comorbidities), who underwent ESG from August 2013 to August 2019 for treatment of obesity were enrolled. Patients were followed for up to 5 years after their procedure. The primary outcome was weight loss at 5 years after the procedure (% total body weight loss, TBWL) Results: 216 patients (68% female) with a mean age of 46±13 years, and mean BMI of 39±6 kg/m2 underwent ESG. Out of 216 patients, 203, 96, and 68 patients were eligible for a 1-, 3-, and 5-year follow up, with complete follow-up rates of 70%, 71%, and 82%, respectively. At 5 years, mean TBWL was 15.9% (95% CI, 11.7-20.5, p < .001) and 90 and 61% of patients maintained 5 and 10% TBWL, respectively. There was an overall rate of 1.3% moderate adverse events (AEs), without any severe or fatal AEs. Conclusions: Our results suggest that ESG is safe and effective for treatment of obesity, with durable long-term results for at least up to 5 years after the procedure. This procedure should be considered as a reliable option for treatment of obesity.
KW - Bariatrics
KW - Endoscopy
KW - Gastroplasty
KW - Obesity
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85100895481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100895481&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.09.055
DO - 10.1016/j.cgh.2020.09.055
M3 - Article
C2 - 33011292
AN - SCOPUS:85100895481
SN - 1542-3565
VL - 19
SP - 1051-1057.e2
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 5
ER -